Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403418 | 1.00 | ACE (0.51) | ACELMNAPREPPRCPSMN1; SMN2 | |
| SCHEMBL6352076 | 0.84 | ACE (0.54) | ACELMNASMN1; SMN2F2ACE2 | |
| SCHEMBL13008125 | 0.83 | PREP (0.52) | PREPPRCPFKBP1AMEN1NPC1 | |
| SCHEMBL3393053 | 0.83 | PREP (0.52) | PREPPRCPFKBP1AMEN1NPC1 | |
| SCHEMBL3393088 | 0.81 | ACE (0.55) | ACELMNASMN1; SMN2FKBP1A | |
| SCHEMBL13008499 | 0.81 | ACE (0.55) | ACELMNASMN1; SMN2FKBP1A | |
| SCHEMBL9545364 | 0.79 | FKBP1A (0.55) | PRCPSMN1; SMN2F2FKBP1AMEN1 | |
| SCHEMBL26616519 | 0.79 | PREP (0.60) | ACEPREPF2FKBP1AMEN1 | |
| SCHEMBL26616511 | 0.79 | PREP (0.60) | ACEPREPF2FKBP1AMEN1 | |
| SCHEMBL9337656 | 0.78 | PREP (0.59) | ACEPREPFKBP1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737819-B1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS BV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | DSM IP ASSETS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | DSM IP ASSETS B.V. (NL) | 2008-09-25 | — | — | US | disclosed |
| EP-1737819-A1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSMIP Assets B.V. (NL) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005092850-A1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS B.V. (NL) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | NGLY1, HRH4, C3AR1 | ACE 1987/4885LMNA 3842/4885PREP 137/4885 |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | NGLY1, HRH4, C3AR1 | ACE 1987/4885LMNA 3842/4885PREP 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.